CN107257683A - C1酯酶抑制剂的药物制剂 - Google Patents

C1酯酶抑制剂的药物制剂 Download PDF

Info

Publication number
CN107257683A
CN107257683A CN201680010988.7A CN201680010988A CN107257683A CN 107257683 A CN107257683 A CN 107257683A CN 201680010988 A CN201680010988 A CN 201680010988A CN 107257683 A CN107257683 A CN 107257683A
Authority
CN
China
Prior art keywords
inh
pharmaceutical formulation
formulation
mosm
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680010988.7A
Other languages
English (en)
Chinese (zh)
Inventor
W·舍费尔
E-J·坎茨
H·梅岑
F·迈
I·普拉格斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CN107257683A publication Critical patent/CN107257683A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680010988.7A 2015-02-20 2016-02-19 C1酯酶抑制剂的药物制剂 Pending CN107257683A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15156010 2015-02-20
EP15156010.9 2015-02-20
PCT/EP2016/053559 WO2016131958A1 (en) 2015-02-20 2016-02-19 Pharmaceutical formulations of c1 esterase inhibitor

Publications (1)

Publication Number Publication Date
CN107257683A true CN107257683A (zh) 2017-10-17

Family

ID=52573617

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680010988.7A Pending CN107257683A (zh) 2015-02-20 2016-02-19 C1酯酶抑制剂的药物制剂

Country Status (13)

Country Link
US (1) US20180036394A1 (enExample)
EP (1) EP3258911A1 (enExample)
JP (1) JP6516855B2 (enExample)
KR (1) KR20170118856A (enExample)
CN (1) CN107257683A (enExample)
AU (1) AU2016221627A1 (enExample)
BR (1) BR112017017685A2 (enExample)
CA (1) CA2977090A1 (enExample)
IL (1) IL253824A0 (enExample)
MX (1) MX2017010323A (enExample)
RU (1) RU2017132449A (enExample)
SG (1) SG11201706019XA (enExample)
WO (1) WO2016131958A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120381522A (zh) * 2025-04-02 2025-07-29 南方医科大学南方医院 一种治疗肝硬化门脉高压的化合物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010656A (zh) * 2011-09-24 2014-08-27 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
WO2014145519A2 (en) * 2013-03-15 2014-09-18 Viropharma Holdings Limited C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010656A (zh) * 2011-09-24 2014-08-27 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
WO2014145519A2 (en) * 2013-03-15 2014-09-18 Viropharma Holdings Limited C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120381522A (zh) * 2025-04-02 2025-07-29 南方医科大学南方医院 一种治疗肝硬化门脉高压的化合物及其应用
CN120381522B (zh) * 2025-04-02 2026-01-23 南方医科大学南方医院 一种治疗肝硬化门脉高压的化合物及其应用

Also Published As

Publication number Publication date
JP2018509398A (ja) 2018-04-05
MX2017010323A (es) 2017-12-07
IL253824A0 (en) 2017-09-28
US20180036394A1 (en) 2018-02-08
AU2016221627A1 (en) 2017-08-17
SG11201706019XA (en) 2017-09-28
EP3258911A1 (en) 2017-12-27
BR112017017685A2 (pt) 2018-04-10
RU2017132449A (ru) 2019-03-21
CA2977090A1 (en) 2016-08-25
KR20170118856A (ko) 2017-10-25
JP6516855B2 (ja) 2019-05-22
WO2016131958A1 (en) 2016-08-25
RU2017132449A3 (enExample) 2019-09-05

Similar Documents

Publication Publication Date Title
US11633462B2 (en) Pharmaceutical composition comprising plasminogen and uses thereof
KR102579789B1 (ko) C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
US20180036411A1 (en) Stable Formulation of Insulin Glulisine
TWI635874B (zh) 艾妥鈣塞(etelcalcetide)(amg 416)之穩定液體調配物
US20230414698A1 (en) Collagen 7 compositions and methods of using the same
JP2024174107A (ja) インスリンプレミックスの配合物と製品、それを調製する方法、及びそれを使用する方法
JP6516855B2 (ja) Ｃ１エステラーゼ阻害剤の医薬製剤
US11554156B2 (en) Pharmaceutical formulations of C1 esterase inhibitor
JP2023062160A (ja) グルコセレブロシダーゼ及びイソファゴミンを含む製剤
US20240424055A1 (en) Administration of c5-binding proteins
BR112017012972B1 (pt) Composição farmacêutica que compreende plasminogênio e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171017